重症COVID-19患者持续性肺泡炎症反应与死亡率相关
本研究为观察性队列研究,在154例COVID-19相关ARDS患者中重复检测支气管肺泡灌洗液和血浆的63种生物标志物。发现13种固有免疫激活标志物呈肺泡而非全身性炎症,肺泡CCL20和CXCL1纵向升高与死亡率增加相关,高剂量类固醇治疗与肺泡CCL20和CXCL1水平下降相关。
要点
- COVID-19相关ARDS患者存在肺泡固有免疫炎症状态,与较高死亡率相关。
- 肺泡CCL20和CXCL1浓度纵向升高与死亡率增加相关。
- 高剂量类固醇治疗与肺泡CCL20和CXCL1水平下降相关。
核心结论
- COVID-19相关ARDS患者存在与固有宿主反应相关的肺泡炎症状态,该状态与较高死亡率相关。
- 高剂量类固醇治疗与肺泡CCL20和CXCL1浓度下降相关。
研究设计与样本
- 观察性队列研究,纳入154例COVID-19患者,分析284份支气管肺泡灌洗液和配对血浆样本,检测63种生物标志物。
主要发现
- 13种提示固有免疫激活的生物标志物表现为肺泡而非全身性炎症。
- 包括CCL20和CXCL1在内的多种固有免疫标志物肺泡浓度纵向升高与死亡率增加相关。
- 高剂量类固醇治疗与后续肺泡CCL20和CXCL1水平下降相关。
临床怎么用
- 肺泡固有免疫炎症标志物可能有助于评估COVID-19相关ARDS患者的死亡风险。
- 高剂量类固醇治疗可能影响肺泡CCL20和CXCL1水平,但需进一步研究确认临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with COVID-19-related acute respiratory distress syndrome (ARDS) show limited systemic hyperinflammation, but immunomodulatory treatments are effective. Little is known about the inflammatory response in the lungs and if this could be targeted using high-dose steroids (HDS). We aimed to characterise the alveolar immune response in patients with COVID-19-related ARDS, to determine its association with mortality, and to explore the association between HDS treatment and the alveolar immune response. METHODS: In this observational cohort study, a comprehensive panel of 63 biomarkers was measured in repeated bronchoalveolar lavage (BAL) fluid and plasma samples of patients with COVID-19 ARDS. Differences in alveolar-plasma concentrations were determined to characterise the alveolar inflammatory response. Joint modelling was performed to assess the longitudinal changes in alveolar biomarker concentrations, and the association between changes in alveolar biomarker concentrations and mortality. Changes in alveolar biomarker concentrations were compared between HDS-treated and matched untreated patients. RESULTS: 284 BAL fluid and paired plasma samples of 154 patients with COVID-19 were analysed. 13 biomarkers indicative of innate immune activation showed alveolar rather than systemic inflammation. A longitudinal increase in the alveolar concentration of several innate immune markers, including CC motif ligand (CCL)20 and CXC motif ligand (CXCL)1, was associated with increased mortality. Treatment with HDS was associated with a subsequent decrease in alveolar CCL20 and CXCL1 levels. CONCLUSIONS: Patients with COVID-19-related ARDS showed an alveolar inflammatory state related to the innate host response, which was associated with a higher mortality. HDS treatment was associated with decreasing alveolar concentrations of CCL20 and CXCL1.
引用
- de Brabander J, Boers LS, Kullberg RFJ, et al. Persistent alveolar inflammatory response in critically ill patients with COVID-19 is associated with mortality. Thorax. 2023. PMID: 37142421. doi:10.1136/thorax-2023-219989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。